The Role of Endocannabinoid System in Neuroprotection: Molecular Targets and Therapeutic Opportunities

被引:1
|
作者
Thapa, Sonia [1 ,2 ]
Singh, Shashank K. [1 ,2 ]
机构
[1] CSIR Indian Inst Integrat Med, Canc Pharmacol Div, Canal Rd, Jammu 180001, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad, India
来源
INTEGRATIVE MEDICINE REPORTS | 2023年 / 2卷 / 01期
关键词
cannabinoids; neurotransmitters; pain; cannabinoid receptors; neurological disorders; CB1; CANNABINOID-RECEPTOR; NEUROPATHIC PAIN; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; ABNORMAL-CANNABIDIOL; SELECTIVE ANTAGONIST; PARTIAL AGONIST; FULL AGONIST; GLUTAMATE; ACTIVATION;
D O I
10.1089/imr.2022.0091
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: To describe the endocannabinoid system, cannabinoid receptors, its agonism/antagonism in neurodegenerative disorders.Introduction: The endocannabinoid system (ECS) represents a highly complex biological system that synthesize and degrade the endocannabinoids. Cannabinoids are endogenous lipid-based neurotransmitters, work in retrograde manner, that bind to a class of G protein-coupled receptors (GPCRs) known as CBRs, of two types: CB1R and CB2R.Results: The literature review suggests that the endocannabinoids regulate cognitive processes, fertility, pregnancy, immune homeostasis, appetite, pain, pain sensation, memory, and behavior. Both CB1 and CB2 couple mainly to inhibitor G proteins and having same pharmacological influences as other GPCRs. Thus, selective/partial agonism, functional selectivity/activity, and inverse agonism all play vital activities in determining the cellular response to specific CBR and ligand interactions.Conclusion: Improved therapeutic modalities for neurological disorders and the development of novel molecular targets for therapeutic intervention of neuronal diseases require a full understanding of the cross-talk between CB1, cannabinoids, and pathophysiology of neurodegenerative disease.
引用
收藏
页码:72 / 86
页数:15
相关论文
共 50 条
  • [31] Integrins as therapeutic targets: lessons and opportunities
    Dermot Cox
    Marian Brennan
    Niamh Moran
    Nature Reviews Drug Discovery, 2010, 9 : 804 - 820
  • [32] Therapeutic opportunities and targets in childhood leukemia
    Ford A.M.
    Martínez-Ramírez Á.
    Clinical and Translational Oncology, 2006, 8 (8) : 560 - 565
  • [33] Integrins as therapeutic targets: lessons and opportunities
    Cox, Dermot
    Brennan, Marian
    Moran, Niamh
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) : 804 - 820
  • [34] The endocannabinoid system and its therapeutic exploitation
    Di Marzo, V
    Bifulco, M
    De Petrocellis, L
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (09) : 771 - 784
  • [35] The endocannabinoid system as a target for therapeutic drugs
    Piomelli, D
    Giuffrida, A
    Calignano, A
    de Fonseca, FR
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (06) : 218 - 224
  • [36] Molecular Targets Involved in the Neuroprotection Mediated by Terpenoids
    Gonzalez-Cofrade, Laura
    de las Heras, Beatriz
    Apaza Ticona, Luis
    Palomino, Olga M.
    PLANTA MEDICA, 2019, 85 (17) : 1304 - 1315
  • [37] The endocannabinoid system and its therapeutic exploitation
    Vincenzo Di Marzo
    Maurizio Bifulco
    Luciano De Petrocellis
    Nature Reviews Drug Discovery, 2004, 3 : 771 - 784
  • [38] The Endocannabinoid System as a Therapeutic Target in Glaucoma
    Cairns, Elizabeth A.
    Baldridge, William H.
    Kelly, Melanie E. M.
    NEURAL PLASTICITY, 2016, 2016
  • [39] Therapeutic potential of the endocannabinoid system in the brain
    Ramos, JA
    González, S
    Sagredo, O
    Gómez-Ruiz, M
    Fernández-Ruiz, J
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (07) : 609 - 617
  • [40] The endocannabinoid system and cancer: therapeutic implication
    Guindon, Josee
    Hohmann, Andrea G.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (07) : 1447 - 1463